IntrinsicIntrinsic
← All summaries

BIO-TECHNE Corp

TECH
Financials & Chart →

Business Summary

Bio-Techne Corporation operates in the life science reagents, instruments, and services markets for research, diagnostics, and bioprocessing worldwide. The company manages two operating segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment is the larger, representing approximately 72% of net sales in fiscal 2026, and includes reagents, antibodies, small molecules, tissue culture sera, and cell selection technologies, as well as analytical tools for protein analysis. The Diagnostics and Spatial Biology segment represents approximately 28% of net revenues and includes diagnostic products, spatial biology assays, and genetic and oncology kits. The company operates globally with offices throughout North America, Europe, and Asia, and manufactures products in multiple locations in North America, the U.K., Canada, Switzerland, and China.

The company faces intense competition across most product lines, with competitors ranging from start-ups to large multinational companies. Key competitive factors include price, quality, performance, delivery speed, application expertise, service, technology, distribution network, and brand recognition. The company believes its competitive position is strong due to the unique aspects of many of its products and product quality. No single end-user customer accounted for more than 10% of the Protein Sciences segment's net sales during fiscal 2026, 2025, or 2024, and no customer accounted for 10% or more of the Diagnostics and Spatial Biology segment's consolidated net sales during those periods.

The company generates revenue through the sale of life science reagents, instruments, and services. Revenue is derived from consumables, instruments, services, and royalties. The company sells products directly to customers primarily in North America, Europe, and China, and through distributors in other regions. The Protein Sciences segment sells to researchers in academia and industry, including pharmaceutical and biotech companies, and to diagnostic and therapeutic customers. The Diagnostics and Spatial Biology segment sells to researchers and to laboratories, with many diagnostic products sold on an OEM basis.

The Protein Sciences segment includes the Reagent Solutions division, offering specialized proteins, antibodies, small molecules, tissue culture sera, and cell selection technologies, and the Analytical Solutions division, offering manual and automated protein analysis instruments and immunoassays. Key product brands include R&D Systems, Tocris Biosciences, Novus Biologicals, and ProteinSimple. The segment also includes a 19.9% investment in Wilson Wolf, a provider of cell culture devices for cell-based therapies, with the remaining ownership to be acquired by the end of calendar year 2027.

The Diagnostics and Spatial Biology segment includes the Spatial Biology division, offering in-situ hybridization assays under the ACD brand and the COMET instrument from Lunaphore, and the Bio-Techne Diagnostic division, offering regulated products such as calibrators and controls, and Asuragen-branded genetic and oncology products. The segment focuses on spatial biology, liquid biopsy, molecular diagnostics kits, and diagnostics reagents.

In fiscal 2026, the company introduced over 1,900 new products. On June 25, 2026, the company entered into a Merger Agreement with Merck KGaA, Darmstadt, Germany, under which each share of common stock will be converted into the right to receive $73.00 in cash. The Merger is expected to close by late 2026 or early 2027. The company also continued restructuring actions, including a plan to recover operating margins and a plan to optimize global manufacturing.

The company's fiscal 2026 net sales were $1.2 billion, compared to $1.2 billion in fiscal 2025 and $1.2 billion in fiscal 2024. Net earnings were $165.0 million in fiscal 2026, compared to $176.4 million in fiscal 2025 and $202.3 million in fiscal 2024. Diluted earnings per share were $1.04 in fiscal 2026, compared to $1.11 in fiscal 2025 and $1.27 in fiscal 2024.

Business Outlook

The company's growth strategy includes expanding into high-potential markets, particularly in China, India, and developing countries, through distribution and direct operations. The company also plans to leverage its strong balance sheet to acquire new technologies and products. The pending Merger with Merck KGaA is expected to close by late 2026 or early 2027, subject to regulatory approvals and shareholder approval.

The company plans to continue investing in research and development to introduce new products, with over 1,900 new products introduced in fiscal 2026. The company also plans to expand its sales staff and distribution channels globally to increase its presence and make it easier for customers to transact with the company.

The company is executing restructuring plans to recover operating margins and optimize global manufacturing. These actions are expected to reduce costs and improve efficiency, though specific targets were not disclosed in the filing.

The company's capital allocation priorities include funding research and development, capital expenditures, and potential acquisitions. The company has a revolving credit facility of $1 billion, which can be increased by an additional $400 million, and had drawn $200 million as of August 17, 2026. The company has historically paid quarterly dividends, but is prohibited from declaring dividends other than regular quarterly cash dividends consistent with past policy while the Merger Agreement is in effect.

The company faces headwinds from global economic conditions, including slower growth, inflation, and volatility in credit and currency markets. The company also faces risks from international political and trade tensions, including tariffs, which have increased costs and could disrupt supply chains. The company's business is sensitive to changes in government healthcare policies and research funding.

The company faces execution risks related to the pending Merger, including potential disruption to business relationships, employee retention challenges, and the diversion of management attention. The company may be required to pay a termination fee of approximately $230.5 million if the Merger Agreement is terminated under specified circumstances.

Risk Factors

The company's business is sensitive to global economic conditions, and slower growth or deterioration in the global economy could adversely affect customer orders and demand for products. Approximately 48% of sales revenue in fiscal 2026 came from outside the U.S., exposing the company to international political, compliance, and business risks, including tariffs and trade tensions. The pending Merger with Merck KGaA could disrupt business relationships, and if the Merger is not completed, the company may be required to pay a termination fee of approximately $230.5 million. The company relies on third-party package-delivery services, and a significant disruption or price increase could disrupt shipping and lower profitability. The company's manufacturing operations are subject to complex regulations, and any failure to comply could result in recalls, penalties, or shutdown of production facilities.

Management Priorities

Management's message emphasizes the company's commitment to its strategic pillars: growing and leveraging the core business, capitalizing on high-potential markets, expanding through innovation and acquisition, delivering best-in-class customer experience, and developing people through a transformative culture. The company highlights its strong financial position and its ability to execute its growth strategy, including through the pending Merger with Merck KGaA, which offers $73.00 per share in cash. Management also emphasizes the importance of its EPIC culture (Empowerment, Passion, Innovation, Collaboration) and its commitment to attracting and retaining top talent.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Protein Sciences Segment
  3. [3] Item 1, Business — Diagnostics and Spatial Biology Segment
  4. [4] Item 1, Business — Competition
  5. [5] Item 1, Business — Protein Sciences Segment
  6. [6] Item 1, Business — Diagnostics and Spatial Biology Segment
  7. [7] Item 1, Business — New Products and Research and Development
  8. [8] Item 1, Business — Pending Merger with Merck KGaA
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Results of Operations
  40. [40] Item 7, MD&A — Results of Operations
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 7, MD&A — Results of Operations
  43. [43] Item 7, MD&A — Results of Operations
  44. [44] Item 7, MD&A — Results of Operations
  45. [45] Item 7, MD&A — Results of Operations
  46. [46] Item 7, MD&A — Results of Operations
  47. [47] Item 7, MD&A — Results of Operations
  48. [48] Item 7, MD&A — Results of Operations
  49. [49] Item 7, MD&A — Results of Operations
  50. [50] Item 7, MD&A — Results of Operations
  51. [51] Item 7, MD&A — Results of Operations
  52. [52] Item 7, MD&A — Results of Operations
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 7, MD&A — Results of Operations
  55. [55] Item 7, MD&A — Results of Operations
  56. [56] Item 7, MD&A — Results of Operations
  57. [57] Item 7, MD&A — Results of Operations
  58. [58] Item 7, MD&A — Results of Operations
  59. [59] Item 7, MD&A — Results of Operations
  60. [60] Item 7, MD&A — Results of Operations
  61. [61] Item 7, MD&A — Results of Operations
  62. [62] Item 7, MD&A — Results of Operations
  63. [63] Item 7, MD&A — Results of Operations
  64. [64] Item 7, MD&A — Results of Operations
  65. [65] Item 7, MD&A — Results of Operations
  66. [66] Item 7, MD&A — Results of Operations
  67. [67] Item 7, MD&A — Results of Operations
  68. [68] Item 7, MD&A — Results of Operations
  69. [69] Item 7, MD&A — Results of Operations
  70. [70] Item 7, MD&A — Results of Operations
  71. [71] Item 7, MD&A — Results of Operations
  72. [72] Item 7, MD&A — Results of Operations
  73. [73] Item 7, MD&A — Results of Operations
  74. [74] Item 7, MD&A — Results of Operations
  75. [75] Item 7, MD&A — Results of Operations
  76. [76] Item 7, MD&A — Results of Operations
  77. [77] Item 7, MD&A — Results of Operations
  78. [78] Item 7, MD&A — Results of Operations
  79. [79] Item 7, MD&A — Results of Operations
  80. [80] Item 7, MD&A — Results of Operations
  81. [81] Item 7, MD&A — Results of Operations
  82. [82] Item 7, MD&A — Results of Operations
  83. [83] Item 7, MD&A — Results of Operations
  84. [84] Item 7, MD&A — Results of Operations
  85. [85] Item 7, MD&A — Results of Operations
  86. [86] Item 7, MD&A — Results of Operations
  87. [87] Item 7, MD&A — Results of Operations
  88. [88] Item 7, MD&A — Results of Operations
  89. [89] Item 7, MD&A — Results of Operations
  90. [90] Item 7, MD&A — Results of Operations
  91. [91] Item 7, MD&A — Results of Operations
  92. [92] Item 7, MD&A — Results of Operations
  93. [93] Item 7, MD&A — Results of Operations
  94. [94] Item 7, MD&A — Results of Operations
  95. [95] Item 7, MD&A — Results of Operations
  96. [96] Item 7, MD&A — Results of Operations
  97. [97] Item 7, MD&A — Results of Operations
  98. [98] Item 7, MD&A — Results of Operations
  99. [99] Item 7, MD&A — Results of Operations
  100. [100] Item 7, MD&A — Results of Operations

Analysis on 8/29/2026